178 related articles for article (PubMed ID: 32818584)
1. Activating mutations of STAT3: Impact on human growth.
Gutiérrez M
Mol Cell Endocrinol; 2020 Dec; 518():110979. PubMed ID: 32818584
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders.
Consonni F; Dotta L; Todaro F; Vairo D; Badolato R
Curr Opin Pediatr; 2017 Dec; 29(6):711-717. PubMed ID: 28914637
[TBL] [Abstract][Full Text] [Related]
3. Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review.
Fabre A; Marchal S; Barlogis V; Mari B; Barbry P; Rohrlich PS; Forbes LR; Vogel TP; Giovannini-Chami L
J Allergy Clin Immunol Pract; 2019; 7(6):1958-1969.e9. PubMed ID: 30825606
[TBL] [Abstract][Full Text] [Related]
4. Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?
.
Sediva H; Dusatkova P; Kanderova V; Obermannova B; Kayserova J; Sramkova L; Zemkova D; Elblova L; Svaton M; Zachova R; Kolouskova S; Fronkova E; Sumnik Z; Sediva A; Lebl J; Pruhova S
Horm Res Paediatr; 2017; 88(2):160-166. PubMed ID: 28253502
[TBL] [Abstract][Full Text] [Related]
5. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome.
Leiding JW; Vogel TP; Santarlas VGJ; Mhaskar R; Smith MR; Carisey A; Vargas-Hernández A; Silva-Carmona M; Heeg M; Rensing-Ehl A; Neven B; Hadjadj J; Hambleton S; Ronan Leahy T; Meesilpavikai K; Cunningham-Rundles C; Dutmer CM; Sharapova SO; Taskinen M; Chua I; Hague R; Klemann C; Kostyuchenko L; Morio T; Thatayatikom A; Ozen A; Scherbina A; Bauer CS; Flanagan SE; Gambineri E; Giovannini-Chami L; Heimall J; Sullivan KE; Allenspach E; Romberg N; Deane SG; Prince BT; Rose MJ; Bohnsack J; Mousallem T; Jesudas R; Santos Vilela MMD; O'Sullivan M; Pachlopnik Schmid J; Průhová Š; Klocperk A; Rees M; Su H; Bahna S; Baris S; Bartnikas LM; Chang Berger A; Briggs TA; Brothers S; Bundy V; Chan AY; Chandrakasan S; Christiansen M; Cole T; Cook MC; Desai MM; Fischer U; Fulcher DA; Gallo S; Gauthier A; Gennery AR; Gonçalo Marques J; Gottrand F; Grimbacher B; Grunebaum E; Haapaniemi E; Hämäläinen S; Heiskanen K; Heiskanen-Kosma T; Hoffman HM; Gonzalez-Granado LI; Guerrerio AL; Kainulainen L; Kumar A; Lawrence MG; Levin C; Martelius T; Neth O; Olbrich P; Palma A; Patel NC; Pozos T; Preece K; Lugo Reyes SO; Russell MA; Schejter Y; Seroogy C; Sinclair J; Skevofilax E; Suan D; Suez D; Szabolcs P; Velasco H; Warnatz K; Walkovich K; Worth A; ; Seppänen MRJ; Torgerson TR; Sogkas G; Ehl S; Tangye SG; Cooper MA; Milner JD; Forbes Satter LR
J Allergy Clin Immunol; 2023 Apr; 151(4):1081-1095. PubMed ID: 36228738
[TBL] [Abstract][Full Text] [Related]
6. Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype.
Faletti L; Ehl S; Heeg M
Biomed J; 2021 Aug; 44(4):412-421. PubMed ID: 34366294
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3.
Tanita K; Sakura F; Nambu R; Tsumura M; Imanaka Y; Ohnishi H; Kato Z; Pan J; Hoshino A; Suzuki K; Yasutomi M; Umetsu S; Okada C; Takagi M; Imai K; Ohara O; Muise AM; Okada S; Morio T; Kanegane H
J Clin Immunol; 2021 May; 41(4):780-790. PubMed ID: 33501615
[TBL] [Abstract][Full Text] [Related]
8. Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations.
Gutiérrez M; Scaglia P; Keselman A; Martucci L; Karabatas L; Domené S; Martin A; Pennisi P; Blanco M; Sanguineti N; Bezrodnik L; Di Giovanni D; Caldirola MS; Azcoiti ME; Gaillard MI; Denson LA; Zhang K; Husami A; Yayah Jones NH; Hwa V; Revale S; Vázquez M; Jasper H; Kumar A; Domené H
Mol Cell Endocrinol; 2018 Sep; 473():166-177. PubMed ID: 29378236
[TBL] [Abstract][Full Text] [Related]
9. Distinct molecular response patterns of activating STAT3 mutations associate with penetrance of lymphoproliferation and autoimmunity.
Jägle S; Heeg M; Grün S; Rensing-Ehl A; Maccari ME; Klemann C; Jones N; Lehmberg K; Bettoni C; Warnatz K; Grimbacher B; Biebl A; Schauer U; Hague R; Neth O; Mauracher A; Pachlopnik Schmid J; Fabre A; Kostyuchenko L; Führer M; Lorenz MR; Schwarz K; Rohr J; Ehl S
Clin Immunol; 2020 Jan; 210():108316. PubMed ID: 31770611
[TBL] [Abstract][Full Text] [Related]
10. Novel STAT-3 gain-of-function variant with hypogammaglobulinemia and recurrent infection phenotype.
Erdős M; Tsumura M; Kállai J; Lányi Á; Nyul Z; Balázs G; Okada S; Maródi L
Clin Exp Immunol; 2021 Sep; 205(3):354-362. PubMed ID: 34050927
[TBL] [Abstract][Full Text] [Related]
11. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations.
Milner JD; Vogel TP; Forbes L; Ma CA; Stray-Pedersen A; Niemela JE; Lyons JJ; Engelhardt KR; Zhang Y; Topcagic N; Roberson ED; Matthews H; Verbsky JW; Dasu T; Vargas-Hernandez A; Varghese N; McClain KL; Karam LB; Nahmod K; Makedonas G; Mace EM; Sorte HS; Perminow G; Rao VK; O'Connell MP; Price S; Su HC; Butrick M; McElwee J; Hughes JD; Willet J; Swan D; Xu Y; Santibanez-Koref M; Slowik V; Dinwiddie DL; Ciaccio CE; Saunders CJ; Septer S; Kingsmore SF; White AJ; Cant AJ; Hambleton S; Cooper MA
Blood; 2015 Jan; 125(4):591-9. PubMed ID: 25359994
[TBL] [Abstract][Full Text] [Related]
12. A novel gain-of-function STAT3 variant in infantile-onset diabetes associated with multiorgan autoimmunity.
Zhou Q; Chen D; Yu J; Zheng B; Zhou W; Jia Z; Zhang A; Gu W
Mol Genet Genomic Med; 2024 Feb; 12(2):e2407. PubMed ID: 38404237
[TBL] [Abstract][Full Text] [Related]
13. Phenotypes of STAT3 gain-of-function variant related to disruptive regulation of CXCL8/STAT3, KIT/STAT3, and IL-2/CD25/Treg axes.
Marega LF; Sabino JS; Pedroni MV; Teocchi M; Lanaro C; de Albuquerque DM; Dos Santos IP; Costa FF; Dos Santos Vilela MM
Immunol Res; 2021 Oct; 69(5):445-456. PubMed ID: 34390446
[TBL] [Abstract][Full Text] [Related]
14. STAT3 gain-of-function mutation in an adult patient.
López AL; Niemela J; Stoddard J; Paolini MV; Rosenzweig S; Fernández Romero DS
Medicina (B Aires); 2021; 81(6):1065-1068. PubMed ID: 34875609
[TBL] [Abstract][Full Text] [Related]
15. STAT3 Gain-of-Function Mutations Underlie Deficiency in Human Nonclassical CD16
Korenfeld D; Roussak K; Dinkel S; Vogel TP; Pollack H; Levy J; Leiding JW; Milner J; Cooper M; Klechevsky E
J Immunol; 2021 Nov; 207(10):2423-2432. PubMed ID: 34654687
[TBL] [Abstract][Full Text] [Related]
16. Human T
Zhang Y; Siegel AM; Sun G; Dimaggio T; Freeman AF; Milner JD
J Allergy Clin Immunol; 2019 Mar; 143(3):1108-1118.e4. PubMed ID: 30030006
[TBL] [Abstract][Full Text] [Related]
17. STAT1 and STAT3 mutations: important lessons for clinical immunologists.
Olbrich P; Freeman AF
Expert Rev Clin Immunol; 2018 Dec; 14(12):1029-1041. PubMed ID: 30280610
[TBL] [Abstract][Full Text] [Related]
18. A Novel
Deng M; Li Y; Li Y; Mao X; Ke H; Liang W; Lei X; Lau YL; Mao H
Front Immunol; 2022; 13():866638. PubMed ID: 35677041
[TBL] [Abstract][Full Text] [Related]
19. Dysregulatory syndromes: the role of signal transducers and activators of transcription.
Bezrodnik L; Gaillard MI; Caldirola MS
Curr Opin Pediatr; 2018 Dec; 30(6):821-828. PubMed ID: 30407975
[TBL] [Abstract][Full Text] [Related]
20. Type 1 Diabetes in STAT Protein Family Mutations: Regulating the Th17/Treg Equilibrium and Beyond.
Fabbri M; Frixou M; Degano M; Fousteri G
Diabetes; 2019 Feb; 68(2):258-265. PubMed ID: 30665954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
